|
|
|
| Effect of Leuprorelin Acetate Combined with Dydrogesterone on Ovarian Endometriosis Patients and its Influence on Postoperative Recurrence |
| JIANG Li, FAN Yating, WANG Ying, et al |
| Department of Gynecology, Baoji High-tech Zone Hospital, Baoji Shaanxi 721300 |
|
|
|
|
Abstract 【Objective】To investigate the effect of Leuprorelin acetate combined with Dydrogesterone on ovarian endometriosis patients and its influence on postoperative recurrence. 【Methods】A total of 110 patients with ovarian endometriosis admitted to Baoji High-tech Zone Hospital from August 2019 to June 2021 were selected and divided into observation group and control group according to the random number table method, with 55 cases in each group. Both groups received laparoscopic surgery. The control group received leuprorelin acetate treatment after surgery, while the observation group received dydrogesterone treatment on the basis of the control group. Both groups were treated for 3 months. The clinical efficacy, adverse reactions, postoperative recurrence, serum luteinizing hormone (LH), follicle-stimulating hormone (FSH), estradiol (E2), visual analogue scale (VAS) scores for pelvic pain, dysmenorrhea, and dyspareunia before and after treatment were compared between the two groups. 【Results】One year after treatment, the total effective rate of the observation group was higher than that of the control group (P<0.05). After treatment, the serum FSH, LH, E2 levels of both groups were lower than those before treatment (P<0.05), and the serum FSH, LH, E2 levels of the observation group were lower than those of the control group (P<0.05). After treatment, the VAS scores for pelvic pain, dysmenorrhea, and dyspareunia in both groups were lower than those before treatment (P<0.05), and the VAS scores for pelvic pain, dysmenorrhea, and dyspareunia in the observation group were lower than those in the control group (P<0.05). There was no significant difference in the total incidence of adverse reactions between the two groups (P>0.05). During the follow-up period of one year, one patient in the control group and two patients in the observation group were lost to follow-up, resulting in a follow-up rate of 97.27%(107/110). The postoperative recurrence rate in the observation group (3.77%) was lower than that in the control group (16.67%) (P<0.05). 【Conclusion 】 Leuprorelin acetate combined with Dydrogesterone is effective in treating ovarian endometriosis. It can improve serum hormone levels, reduce pelvic pain, dysmenorrhea, dyspareunia, and postoperative recurrence risk with good safety and reliability.
|
|
Received: 01 August 2023
|
|
|
|
|
|
[1] 吴金萍,韩钦维,李妙妮. 子宫内膜异位症患者血清miRNA-93水平与不孕的相关性分析[J].医学临床研究,2021,38(2):220-222.
[2] 肖继伟,王晓燕,万钰磊. 肺部子宫内膜异位症误诊分析[J].临床误诊误治,2020,33(4):13-17.
[3] 王莱娜,张萍. 卵巢型子宫内膜异位症初次腹腔镜保守性手术后复发的相关因素分析[J].现代医学,2022,50(2):231-236.
[4] 张靖雪,周夏伶,何伟,等. 腹腔镜联合醋酸亮丙瑞林对子宫内膜异位症合并不育症疗效[J].中国计划生育学杂志,2021,29(1):21-24.
[5] 任英俊,王晓倩. 地屈孕酮片联合心理干预对子宫内膜异位症痛经患者的效果[J].国际精神病学杂志,2022,49(3):495-497.
[6] DARAI E, PLOTEAU S, BALLESTER M, et al. Pathogenesis, genetics and diagnosis of endometriosis[J].Presse Med,2017,46(12 Pt 1):1156-1165.
[7] 杨静文,贾平一,邱立新,等. 视觉模拟评分法在前牙种植美学评价中应用的可行性分析[J].中华口腔医学杂志,2021,56(4):324-328.
[8] 甄华龙,黄斌斌,江敏敏,等. 夜间轮班工作对女性生殖健康影响的流行病学研究进展[J].环境与职业医学,2022,39(8):954-958.
[9] 方金华,许莉,原二芳. 腹腔镜手术联合GnRH-a治疗子宫内膜异位症伴不孕症对患者血清自身免疫功能及卵巢功能影响[J].中国计划生育学杂志,2022,30(6):1249-1253.
[10] 赵曰明,刘芳芳,孙海波. 桂枝茯苓联合GnRH-a治疗子宫内膜异位症腹腔镜术后痛经效果[J].中国计划生育学杂志,2022,30(5):1018-1021.
[11] 张宝芹. 腹腔镜联合GnRH-a治疗子宫内膜异位症的临床应用[J].现代科学仪器,2021,38(6):116-119.
[12] 黄新,黄薇. 孕激素治疗子宫内膜异位症的研究进展[J].中华生殖与避孕杂志,2022,42(9):962-966.
[13] 谭细凤,李怀芳,王玉凤,等. 地屈孕酮联合来曲唑治疗对子宫内膜异位症患者性激素、炎症因子、CA125及VEGF的影响[J].基础医学与临床,2019,39(3):392-395.
[14] 任红娟,王学博,孙丽. 地屈孕酮结合芳香化酶抑制剂治疗子宫内膜异位症的临床效果及对血清CA125、MMP-3、VEGF的影响[J].中国计划生育学杂志,2018,26(11):1044-1047.
[15] 夏莹,周晓莉,刘杰,等. 活血通络解毒汤对血瘀蕴毒型子宫内膜异位症患者卵巢功能及血清VEGF、TNF-α、 CA125水平的影响[J].现代中西医结合杂志,2020,29(23):2556-2561.
[16] 兰素伟,王杏茶,王春辉,等. 不同病变类型子宫内膜异位症对卵巢储备功能及辅助生殖技术结果的影响[J].现代生物医学进展,2022,22(18):3554-3557. |
|
|
|
2023, Vol. 40 
